CORT - CORCEPT THERAPEUTICS INC

33.87
-0.170   -0.502%

Share volume: 1,202,725
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$34.04
-0.17
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
60%
Profitability 82%
Dept financing 3%
Liquidity 75%
Performance 48%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.84%
1 Month
-18.01%
3 Months
-59.18%
6 Months
-52.45%
1 Year
-38.86%
2 Year
44.87%
Key data
Stock price
$33.87
P/E Ratio 
37.29
DAY RANGE
$32.99 - $34.18
EPS 
$0.95
52 WEEK RANGE
$28.66 - $117.33
52 WEEK CHANGE
-$39.95
MARKET CAP 
3.661 B
YIELD 
N/A
SHARES OUTSTANDING 
106.374 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-28-2025
BETA 
1.97
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,514,926
AVERAGE 30 VOLUME 
$1,835,270
Company detail
CEO: Joseph K. Belanoff
Region: US
Website: corcept.com
Employees: 300
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the. treatment of hyperglycemia secondary to hypercortisolism in adult patients with. endogenous Cushing's syndrome.

Recent news